Literature DB >> 30668187

The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.

Geneviève I C G Ector1, Tim M Govers1,2, Peter E Westerweel3, Janneke P C Grutters4, Nicole M A Blijlevens1.   

Abstract

Healthcare costs are rising due to an increase in chronic diseases, including chronic myeloid leukemia (CML) due to improved survival. In CML care, patient adherence and physician adherence are key elements. We assessed the potential health gain and cost savings when both are improved, using a decision analytic model that integrated various sources of evidence. The current situation was compared to a theoretical situation in which either patient or physician adherence is improved, in terms of costs and quality-adjusted life years (QALYs). Current patient adherence rate is 74%, improvement to 100% resulted in 0.1031 QALYs gained and a saving of €17,509 per patient over a 25-year period. Improving physician adherence from 72% to 100%, resulted in 0.0380 QALYs and €7606. Enhancement of either adherence results in substantial health gain and cost savings. Regarding the rising healthcare costs, new strategies should focus on improving adherence to keep healthcare affordable in the future.

Entities:  

Keywords:  Chronic myelogenous leukemia (CML); cost and cost analysis; guideline adherence; treatment adherence and compliance

Year:  2019        PMID: 30668187     DOI: 10.1080/10428194.2018.1535113

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

Review 1.  A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.

Authors:  Valentin García-Gutiérrez; Massimo Breccia; Elias Jabbour; Michael Mauro; Jorge E Cortes
Journal:  J Hematol Oncol       Date:  2022-07-11       Impact factor: 23.168

2.  Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling.

Authors:  Janneke P C Grutters; Tim Govers; Jorte Nijboer; Marcia Tummers; Gert Jan van der Wilt; Maroeska M Rovers
Journal:  Int J Health Policy Manag       Date:  2019-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.